文献速递泌尿系感染前列腺增生与排尿功能障碍

5α-还原酶抑制剂与SARS-CoV-2感染风险降低相关:配对注册分析

5α-Reductase Inhibitors Are Associated with Reduced Risk of SARS-CoV-2 Infection: A Matched-Pair, Registry-Based Analysis.
PubMed 文献 · J Urol · 2021-08-26

该研究基于前瞻性注册数据,纳入2020年3月8日至2021年2月15日期间接受SARS-CoV-2检测的60,474名男性,采用配对队列设计比较5ARI使用者与非使用者的感染风险。结果显示5ARI使用者感染绝对风险显著降低(42.3% vs 47.2%,ARR 4.9%,OR 0.81,95%CI 0.67-0.97,p=0.026),全队列多变量回归验证 protective 关联(ARR 5.3%,OR 0.877,95%CI 0.774-0.995,p=0.042),但与疾病严重程度无关。

要点

  • 5ARI使用与社区获得性SARS-CoV-2感染风险降低相关。
  • 配对分析示感染绝对风险降低4.9%(OR 0.81,95%CI 0.67-0.97)。
  • 5ARI使用与COVID-19疾病严重程度无显著关联。

核心结论

  • 在无前列腺癌的男性中,5ARI使用与社区获得性SARS-CoV-2感染减少相关。

研究设计与样本

  • 前瞻性注册队列研究,纳入60,474名接受SARS-CoV-2检测的男性,采用1:1配对队列设计,并以全队列多变量逻辑回归验证。

主要发现

  • 匹配队列各944人,5ARI使用者感染绝对风险42.3%(399/944),非使用者47.2%(446/944),ARR 4.9%,OR 0.81(95%CI 0.67-0.97),p=0.026。
  • 全队列55,100人多变量分析证实保护关联:ARR 5.3%,OR 0.877(95%CI 0.774-0.995),p=0.042。
  • 5ARI使用与疾病严重程度无显著关联。

临床怎么用

  • 对于使用5ARI的男性患者,可提示其SARS-CoV-2感染风险可能较低,但不应改变常规用药指征。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has a disproportionately severe effect on men, suggesting that the androgen pathway plays a role in the disease. Studies on the effect of castration and androgen receptor blockade have been mixed, while 5α-reductase inhibitor (5ARI) use in men with COVID-19 (2019 novel coronavirus) have shown potential benefits. We assessed the association of 5ARI use on risk of community acquired SARS-CoV-2 infection. MATERIALS AND METHODS: A total of 60,474 males in a prospective registry of people tested for SARS-CoV-2 between March 8, 2020 and February 15, 2021 were included. Using a matched cohort design, men using 5ARIs were matched 1:1 to non5ARI users. Independent analysis using unconditional multivariable logistic regression on the entire unmatched data set was completed for validation. Primary outcome measures were the association of 5ARI use on rates of SARS-Cov-2 positivity and disease severity. RESULTS: Of the men 1,079 (1.8%) reported 5ARI use and 55,100 were available for matching. The final matched cohorts included 944 men each. Mean duration of use was 60.4 months (IQR 17-84 months). Absolute risk for infection was significantly lower in 5ARI users compared to nonusers, 42.3% (399/944) vs 47.2% (446/944), respectively (absolute risk reduction [ARR] 4.9%, OR 0.81, 95% CI 0.67-0.97, p=0.026). Unconditional multivariable logistic regression analysis of the entire study cohort of 55,100 men confirmed the protective association of 5ARI use (ARR 5.3%, OR=0.877, 95% CI 0.774-0.995, p=0.042). Use of 5ARIs was not associated with disease severity. CONCLUSIONS: Use of 5ARIs in men without prostate cancer was associated with a reduction in community acquired SARS-CoV-2 infection.

来源:J Urol,查看原文。版权归原作者所有。

引用

  1. Lyon M, Li J, Cullen J, et al. 5α-Reductase Inhibitors Are Associated with Reduced Risk of SARS-CoV-2 Infection: A Matched-Pair, Registry-Based Analysis. J Urol. 2021. PMID: 34433301. doi:10.1097/JU.0000000000002180

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。